Term ended May 29, 2024 · High confidence
20-year base term ended Dec 19, 2023
USPTO later recorded it as expired for non-payment on Apr 21, 2025.
Held by Intarcia Therapeutics, Inc.
Filed Apr 21, 2011 as application 13/091,970 · Granted Mar 19, 2013
Base term plus 162 days of patent term adjustment (USPTO delay)
Today
Term ended May 29, 2024
2003
2026
Clock starts
Dec 19, 2003
Dec 19, 2003
Term ended
May 29, 2024
May 29, 2024
Granted
Mar 19, 2013
Mar 19, 2013
base term
patent term adjustment
after the term ends
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
162
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,731,947, US 7,964,183, to May 29, 2024. The term already ends on or before that date, so the cap shortened nothing.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
9
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 162 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Dec 19, 2003, when application 10/742,730, the earliest non-provisional in its chain, was filed (this one was filed Apr 21, 2011) | Dec 19, 2023 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +162 days, USPTO patent term adjustment record | May 29, 2024 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,731,947, US 7,964,183) | resolves to May 29, 2024, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 2 maintenance fees paid | term ended | High confidence |
| USPTO status record | Recorded as expired for non-payment on Apr 21, 2025, after the term ended | no change | High confidence |
| Computed term end | The steps above, in order | May 29, 2024 | High confidence |
This family
| Application 10/742,730 | Abandoned not computed | not computed |
| US 7,731,947 | In force May 2028 | May 2028 |
| Application PCT/US2004/038409 | PCT application no patent term | no patent term |
| Application 12/315,194 | Abandoned not computed | not computed |
| US 7,964,183 | Term ended Nov 2024 | Nov 2024 |
| US 8,257,691 | Term ended Nov 2024 | Nov 2024 |
| US 8,398,967 | this patent May 2024 | May 2024 |
| US 9,724,293 | Lapsed on the fee record Aug 2021 | Aug 2021 |
8 of 9 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 21, 2011 Reel 26628, frame 839 | Eliaz, Rom Ezer; Zhang, Yuanpeng; Rohloff, Catherine Manya; Weeks, Eric William; Junnarkar, Gunjan | Intarcia Therapeutics, Inc. | Assignment of Assignor's Interest |
| Nov 14, 2012 Reel 29299, frame 678 | Intarcia Therapeutics, Inc. | U.S. Bank National Association, as Collateral Agent | Security Agreement |
| Oct 23, 2015 Reel 36942, frame 544 | U.S. Bank National Association, as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Oct 9, 2019 Reel 50673, frame 20 | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Midcap Financial Trust, As Agent | Security Interest |
| Oct 23, 2019 Reel 50801, frame 267 | Intarcia Therapeutics, Inc. | Baupost Private Investments Bviv-3, L.L.C., as Collateral Agent | Security Interest |
| Jan 29, 2020 Reel 51739, frame 453 | Baupost Private Investments Bviv-3, L.L.C. as Collateral Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 Reel 52433, frame 1 | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc.; Intarcia Ireland Limited | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Therapeutics, Inc. | Release of Security Interest |
| Apr 17, 2020 reel/frame not recorded | Midcap Financial Trust, As Agent | Intarcia Ireland Limited | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
The 162 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,731,947, US 7,964,183, ends no earlier than this term, so it caps nothing.
Citations
27
later US patents cite this one
That is top 25% of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.